NucleaBio.com
Based in Pittsfield, Massachusetts, the researchers at Nuclea Biotechnologies take pride in the medical tools they have developed to help physicians and patients chart a treatment plan capable of triumphing over numerous terminal disorders. The firm's DecisionDX™ platform pinpoints genes, proteins, and other biomarkers linked to several diseases, subsequently sorting through molecular and genetic data to produce diagnoses to assist in formulating treatment plans.
Nuclea Biotechnologies developed DecisionDX™ in pursuit of its company-wide mission: to more quickly and accurately detect and diagnose terminal disorders in their beginning phases, when discovery most often leads to successful prevention. The technology provides a great array of vastly improved treatment plans available for use by physicians.
When developing new technology, Nuclea Biotechnologies' researchers focus on biomarker discovery capabilities; clinical lab services, including digital access to relevant cases and documentation; and companion diagnostics, such as a deep-tissue repository and alliances with noteworthy leaders throughout the medical and science fields. Partners such as the Dana Farber Cancer Institute, Johns Hopkins Medicine, and Boston Medical Center have helped Nuclea Biotechnologies further its goals of research and diagnosis.
Additionally, Nuclea Biotechnologies develops numerous programs which involve the Pittsfield community. In 2010, the company launched the Summer Science Institute, which invites 100 high school and college students to attend free science sessions at Berkshire Community College. The Summer Science Institute also encourages active participation through guest speakers and laboratory exercises.
